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There is currently no therapeutic drug treatment for traumatic brain injury (TBI) despite 
decades of experimental clinical trials. This may be because the mechanistic pathways 
for improving TBI outcomes have yet to be identified and exploited. As such, there 
remains a need to seek out new molecular targets and their drug candidates to find 
new treatments for TBI. This review presents supporting evidence for cathepsin B, a 
cysteine protease, as a potentially important drug target for TBI. Cathepsin B expression 
is greatly up-regulated in TBI animal models, as well as in trauma patients. Importantly, 
knockout of the cathepsin B gene in TBI mice results in substantial improvements of 
TBI-caused deficits in behavior, pathology, and biomarkers, as well as improvements 
in related injury models. During the process of TBI-induced injury, cathepsin B likely 
escapes the lysosome, its normal subcellular location, into the cytoplasm or extracellular 
matrix (ECM) where the unleashed proteolytic power causes destruction via necrotic, 
apoptotic, autophagic, and activated glia-induced cell death, together with ECM break-
down and inflammation. Significantly, chemical inhibitors of cathepsin B are effective 
for improving deficits in TBI and related injuries including ischemia, cerebral bleeding, 
cerebral aneurysm, edema, pain, infection, rheumatoid arthritis, epilepsy, Huntington’s 
disease, multiple sclerosis, and Alzheimer’s disease. The inhibitor E64d is unique among 
cathepsin B inhibitors in being the only compound to have demonstrated oral efficacy 
in a TBI model and prior safe use in man and as such it is an excellent tool compound 
for preclinical testing and clinical compound development. These data support the 
conclusion that drug development of cathepsin B inhibitors for TBI treatment should be 
accelerated.
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introduction
Traumatic brain injury (TBI) occurs when an external force, such 
as that due to a vehicular accident, a football collision, or a bullet, 
causes brain dysfunction and pathology. Unfortunately, TBI is all 
too common with over 10 million people worldwide afflicted each 
year (1) and at least 1.7 million cases annually in the United States 
where it is a leading cause of death among the young and the elderly 
(2, 3). Falls are the primary cause of TBI among the very young and 
old, whereas auto accidents and sports injuries are the main cause 
in 15- to 24-year-olds and most of those occur in males (2, 4). 
Military casualties add to these numbers with an overwhelming 
number of those due to blast injury and most of those are males (5).
TBI encompasses a continuum of injuries and pathologies 
and is symptomatically classified into mild, moderate, or severe 
based on the level of patient consciousness (6, 7). Much is known 
about the complex consequences of TBI (8, 9) including the 
necrotic and apoptotic neuronal cell death that occurs (10) and 
the TBI-related pathologies, which include, for example, inflam-
mation (11), breakdown of vascular walls (12), ischemia (13), 
subarachnoid aneurysms and hemorrhages (14), brain edema 
(15), inflammatory pain (16), increased intracranial pressure 
(ICP) (17), infections (18), and neuroexcitatory toxicity (19). 
Moreover, sufficiently severe or repetitive TBI results in increased 
risks for many age-related neurological diseases, including 
amyotrophic lateral sclerosis (ALS) (20), Parkinson’s disease (PD) 
(21), Alzheimer’s disease (AD) (22), epilepsy (23), and possibly 
multiple sclerosis (MS) (24). As such, TBI can also be viewed as a 
model of neurodegenerative diseases generally (25).
But despite this knowledge, there is currently no pharmaceuti-
cally effective treatment for TBI even though many experimental 
clinical trials have been conducted over decades to find such 
(26–28). This may be because the drug targets, which affect 
outcomes, have yet to be identified and exploited and thus there 
is a continuing need for new TBI therapeutic targets.
Proteases and small molecule protease inhibitors are a proven 
target and means for successful pharmaceutical intervention as 
such inhibitors are approved for drug use to treat hypertension 
(29), HIV infection (30), and multiple myeloma cancer (31). The 
cysteine protease, cathepsin B, is a potential drug target for several 
diseases (32), including, for example, various cancers (33–36), 
pancreatitis (37), liver fibrosis (38), rheumatoid arthritis (RA) (39, 
40) viral Ebola (41), bacterial Streptococcus pneumoniae menin-
gitis (42), and parasitic Trypanosoma cruzi infections (43). While 
no cathepsin B inhibitor has yet been approved for drug use, one 
has completed Phase 1 trials for fatty liver disease (44, 45) and 
another is in late preclinical stage for treating Chagas disease (46).
However, cathepsin B’s potential as a TBI drug target has 
received relatively little attention with the last review to discuss 
this protease in a TBI context published a decade ago (47). Since 
then, cathepsin B gene knockout data have clearly demonstrated 
that cathepsin B is a significant cause of the behavioral dysfunc-
tion and pathology that occurs in animal models as a result of 
TBI (48). This review summarizes the evidence showing that 
genetically eliminating or pharmaceutically reducing cathepsin 
B activity produces improved outcomes in animal models of TBI, 
other types of trauma, and the many TBI-related pathologies 
mentioned above. The review also focuses on the small molecule, 
E64d and its derivatives, as a tool compound for developing a 
TBI lead therapeutic because of its demonstrated efficacy by 
many groups by many routes of administration in many TBI and 
TBI-related animal models and its prior safe use in man. The 
paper includes a basic introduction to the enzymology, biology, 
distribution, regulation, and function of cathepsin B and how 
increased expression and redistribution of cathepsin B from lys-
osomes to the cell cytosol and extracellular matrix (ECM) likely 
causes the cathepsin B-induced pathology. The overall conclusion 
drawn is that cathepsin B is an important target for treatment of 
TBI and that E64d and its derivatives have many of the preclinical 
properties needed for a successful TBI therapeutic agent (49–51) 
and should be developed for such.
Cathepsin B Properties: enzymology, 
Genetics, Transcription, and Translation
Cathepsin B enzymology
Cathepsin B is among the most studied proteases as there are 
numerous reports written over the last 76 years. Its proteolytic 
activity was first identified in beef tissue (52). Originally called 
cathepsin II (53), it was renamed cathepsin B 63 years ago (54) and 
was purified 5 years after that (55). The first amino acid sequences 
were determined 32 years ago (56), and the first human, rat, and 
mouse genes were cloned 3 years later (57). The first X-ray crystal 
structure was resolved almost 25 years ago (58). While the first 
report on cathepsin B gene-deficient mice was made 17 years ago 
(59), it was not until last year that such animals were evaluated 
for improving TBI deficits (48).
Endopeptidase and Exopeptidase Activity
Most proteases have either endopeptidase or exopeptidase activ-
ity. Cathepsin B is unusual in having endopeptidase activities 
(60) as well as peptidyl-dipeptidase (61) and carboxypeptidase 
(62) exopeptidase activities. Its multi-enzymatic capability 
is due to a unique structural element of the protein called the 
“occluding loop” (58). At low pH, as occurs in the lysosome, the 
loop closes on the enzymatic active site and does not allow poly-
peptide binding and thereby reduces endopeptidase activity but 
permits peptidyl-dipeptidase and carboxypeptidase activities. At 
higher pH, the loop opens from the active site and allows more 
endopeptidase activity (63). The multiple activities of cathepsin 
B make it particularly well suited among proteases for digesting 
unwanted proteins, but also make it potentially more destructive 
in TBI brain damage and pathology.
Selectivity of Peptide Cleavage Sites
Endopeptidases recognize specific amino acid sequences flanking 
the scissile peptide bond of the cleavage site (64) (see Figure 1). A 
small peptide substrate containing the recognition sequence can 
mimic the recognition site in proteins and can be used to moni-
tor protease activity. Using such substrates, cathepsin B has been 
shown to prefer positively charged arginine (Arg) or lysine (Lys) at 
the P1 position, which is an unusual recognition signal among pro-
teases, and a bulky hydrophobic amino acid residue at P2 (65, 66). 
Cathepsin B will also accept a basic residue, Arg, at the substrate 
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P2 position (67). Thus, the substrate Z-Arg-Arg-AMC (where 
Z =  benzyloxycarbonyl) with AMC (amido-4-methylcoumarin 
hydrochloride) is commonly used to assay cathepsin B activity 
in  vitro as its cleavage liberates fluorescent AMC that monitors 
protease activity. While the recognition motif is not absolute, sig-
nificant changes in the types of amino acids adjacent to the cleav-
age site can drastically affect endopeptidase binding and cleavage.
Classification
Proteases are classified by catalytic type, which are composed of 
aspartic, cysteine, metallo, serine, and threonine, and a small group 
of uncertain catalytic type. Cathepsin B has a reactive cysteine 
residue within its catalytic domain and belongs to the cysteine 
catalytic class. Proteases are further classified according to their 
clan, which is based on the homology of the three-dimensional 
structure, the arrangement of catalytic residues in the active site, 
and the amino acid sequence around the catalytic site. Cathepsin 
B is a member of the CA clan and shares a common structure 
with the dyad reactive cysteine and histidine residues at specific 
positions within the catalytic site (70). They are further classified 
into families in which they are grouped together with proteases 
having a statistically significant relationship in the amino acid 
sequence to a representative member type. The cathepsin B 
sequence is highly homologous to the plant cysteine protease 
papain (56), which is the reference protease of the papain-like 
family. Thus, cathepsin B is a cysteine protease belonging to the 
CA clan and the papain-like family, C1A. The other papain-like 
cysteine proteases in man are cathepsins F, H, C, K, L, O, S, V, 
W, and X. Enzymes as a whole are also systematically classified 
according to the Enzyme Commission (EC) based on a numeri-
cal code related to the type of activity catalyzed by the enzyme 
but not on homology and the enzyme code for cathepsin B is 
EC3.4.22.1.
FiGURe 1 | Protease interactions with polypeptide substrates for 
proteolysis. This figure illustrates protease and polypeptide substrate 
interactions utilizing the Schechter and Berger nomenclature (68). The active 
site of a protease is composed of several subsites. The scheme shows an 
active site of six subsites, termed S1–S3 and S1′–S3′. Subsites are located on 
both sides of the catalytic site and are numbered from there in either direction. 
The positions of the amino acid residues of the peptide substrate represent 
their locations from the cleaved peptide bonds and have the same numbering 
as the subsites they occupy (P1–P3 and P1′–P3′). Cleavage occurs between 
P1 and P1′ residues. Figure revised from Ref. (69).
Common protease names, which are often based on their 
discovery and not on catalytic type or homology, can cause confu-
sion. For example, the name “cathepsin,” which is derived from the 
Greek katehepsin (to digest), was given to the protease activity in 
an acidic environment. Those proteases were subsequently found 
to be of different catalytic types and include the serine proteases 
cathepsins A and G, the aspartic proteases cathepsins D and E, 
and the lysosomal papain-like cysteine proteases (70, 71).
Cathepsin B Genetics
In man, cathepsin B is encoded as a single gene on chromosome 
8 at position p22-23.1 (72), spans 27 kilobases, and contains 
13 exons (73, 74). Interestingly, the gene location of cathepsin 
B on chromosome 8p is near a potential hub for development 
of neuropsychiatric disorders and an area of high divergence 
between chimpanzee and man (75). Human cathepsin B gene 
polymorphisms are associated with the disease tropical calcific 
pancreatitis (76). In mouse, cathepsin B is also encoded as a single 
gene on chromosome 14 at position 33.24, spans 20 kilobases, and 
contains 10 exons and 9 introns (77, 78). The human and mouse 
nucleic acid sequences encoding the proteolytically active form 
have 82% homology (57).
Cathepsin B Transcription
Human cathepsin B messenger ribonucleic acid (mRNA) consists 
of multiple messages that differ in their 5′ and 3′ untranslated 
regions (UTRs) and arise by alternative splicing. Most tissues 
express 2.3 and 4.0 kilobase (kb) transcripts at a ratio of 2:1; but the 
ratio of mRNAs with variant 5′ UTRs differs widely (74). Normal 
human brain contains both cathepsin B mRNA transcripts but 
most is the 2.3 kb form (79).
Small, non-coding microRNA (miRNA) inhibit the expression 
and function of endogenously encoded proteins (80). The miRNA 
TABLe 1 | Cathepsin B is activated in TBi and TBi-related animal models.
Animal model (species) Cathepsin B Reference
mRNA Protein Activity
Trauma TBI (mouse, rat) ↑ ↑ ↑ (48, 93, 94, 
96–98)
Trauma SCC (rat) ↑ ↑ ↑ (99, 100)
Trauma surgery post-op ileus 
(mouse)
nd nd ↑ in ECM (101)
Subarachnoid hemorrhage (rat) nd ↑ nd (102, 103)
Brain aneurysm (rat) ↑ nd ↑ (104)
Chronic hypertension brain 
edema (rat)
nd ↑ nd (105)
Acute ischemic edema (rat) nd ↑ nd (106)
Brain ischemia (monkey, rat) nd ↑ ↑ (106–110)
Neuroexcitatory epilepsy (rat) nd ↑ nd (111)
Neuroexcitatory Huntington’s 
disease (rat)
nd ↑ nd (112)
Infection brain meningitis 
(mouse)
nd nd ↑ (42)
Infection sepsis (rat) nd nd ↑ (113, 114)
Inflammation/pain (mouse) nd ↑ nd (115)
Inflammation/aging (mouse) ↑ ↑ nd (116)
Neurodegenerative ALS 
transgenic (mouse)
↑ nd nd (117, 118)
Neurodegenerative AD 
Transgenic 5XFAD (mouse)
↑ nd nd (119)
Neurodegenerative AD 
Transgenic APPSwe/PS1 
(mouse)
nd ↑ nd (120)
nd, not done; ECM, extracellular matrix; ALS, amyotrophic lateral sclerosis; 5XFAD, 
express APP containing three familial AD mutations (FAD) and human PS1 containing 
two FAD; APPSwe/PS1, express human APP containing one FAD and human PS1 
containing 2 FAD.
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expression patterns vary among organs (81), are altered by central 
nervous system (CNS) injuries, and the changes vary among spinal 
cord contusion (SCC), stroke, and TBI injuries (82). TBI causes 
at least 35 and 50 miRNAs to be up- and down-regulated, respec-
tively, and their predicted targets involve signal transduction, 
transcription, proliferation, and differentiation (83). miR-218 and 
miR-128 down-regulate cathepsin B expression when they are up-
regulated in medulloblastoma cell lines (84) and AD monocytes 
and lymphocytes (85) and are expressed in brain neurons (81, 86).
Cathepsin B Translation
Cathepsin B post-translational processing is well understood and 
has been the subject of many reviews (60, 70, 87). Human cathepsin 
B is initially transcribed as a preproenzyme of 339 amino acids. The 
17 amino acid pre-signal sequence is co-translationally removed 
and the resultant proenzyme is translocated to the Golgi-apparatus 
where aspargine becomes glycosylated by a high-mannose-type 
sugar. The mannose-6-phosphate residues target the proenzyme to 
the lysosomes. The preproenzye or proenzyme forms are not enzy-
matically active. Activation of the proenzyme occurs with cleavage 
of the 62-residue pro region, resulting in mature cathepsin B. The 
mature form (30 kDa) is enzymatically active and can be further 
processed by removal of the C-terminal 6 amino acids and the 
excision of a dipeptide resulting a heavy chain (25 kDa) and a light 
chain (5 kDa). The heavy and light chains form a 2-chain form 
(30 kDa) linked together by a cysteine–cysteine bond. The heavy 
and 2-chain forms are enzymatically active. In some cells, such as 
neuroendocrine cells, cathepsin B is also trafficked to the regulated 
secretory pathway (RSP) but how that occurs is not known. The 
cathepsin B prepro, pro, and mature amino acid sequences of 
mouse and man are 65%, 74%, and 82% homologous, respectively 
(57). Normal human brain contains inactive precursor cathepsin 
B and proteolytically active forms (79).
Proteases are stored in the cell as inactive zymogens that require 
hydrolysis for activation, and allow cells to rapidly deploy active 
protease as needed (88). In the case of cathepsin B, the inactive 
proenzyme is hydrolyzed by a variety of proteases, including the 
aspartic protease cathepsin D, other cysteine proteases, and cath-
epsin B self-cleavage to liberate the mature active form (89–91). 
Maximum cathepsin B zymogen activation occurs at an acidic 
pH and very little occurs at a neutral pH (91), but cathepsin B 
zymogen can endure a neutral pH and be subsequently activated 
in an acidic environment (60). Mature cathepsin B is degraded by 
cysteine protease nicking (87, 92).
Traumatic Brain injury and TBi-Related 
injuries Activate Cathepsin B
PreClinical Data: Cathepsin B in TBi and TBi-
Related Animal Models
TBI Increases Cathepsin B Expression in Animal 
Models
As shown in Table 1, cathepsin B mRNA, protein, and activity 
are increased following trauma in TBI animal models. Trauma 
significantly up-regulates brain cathepsin B mRNA expression 
about 2.5-fold relative to controls at 3 days after TBI in fluid 
percussion injury rat and controlled cortical impact (CCI) 
mouse models (93). Trauma elevated cathepsin B protein levels 
and activity, using a weight drop mouse model, in the cortex 
at the injury site and in the hippocampus distal to the injury 
site beginning as soon as 6  h; the elevated brain cathepsin B 
continued for at least 1  week with a 75% maximum increase 
occurring at about two days post-trauma (94, 95). In a severe 
TBI rat model, brain trauma elevated brain cathepsin B protein 
levels within 1  h and those levels remain elevated for up to 
32 days after injury with a 300% maximum increase at 8 days 
post injury (96). Our data in a severe CCI mouse model show 
a 100% and 380% increase in brain cathepsin B activity and 
protein levels at 2 and 24  h post-trauma, respectively (48). 
Trauma elevates cathepsin B protein levels 1  day to 3  days 
post injury in a moderate closed-skull TBI rat model and this 
increase varied with injury location (97). The prolonged eleva-
tion of cathepsin B after trauma suggests that it may be possible 
to therapeutically intervene clinically, as treatment often does 
not begin until several hours after injury. The fact that different 
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groups using different moderate and severe TBI animal models 
find increased cathepsin B following injury shows that higher 
cathepsin B expression is a consistent response in rodent TBI 
models.
TBI-Related Animal Models
Table 1 shows that cathepsin B expression is increased in several 
TBI-related injuries in animal models. SCC is related to TBI 
in that both are trauma to the CNS and in a SCC rat model, 
cathepsin B mRNA, 37 kDa proprotein, 30 kDa mature protein, 
25 kDa mature protein, and activity increased 20-, 3.5-, 4.5-, 10-, 
and 7-fold, respectively, at the injury site 7  days after trauma 
relative to sham animals (99, 100). Surgery is a form of trauma 
and in a surgical post-operative ileus mouse model, cathepsin B 
activity increased twofold in the ECM on the day after trauma 
relative to control (101) and was accompanied by a loss of the 
ECM microvascular basal lamina and collagen-type IV as is 
characteristically observed in TBI (12). Thus, other trauma 
models also show a similar increase in cathepsin B expression as 
seen in TBI models.
TBI causes many vascular pathologies including ischemia, 
aneurysms, subarachnoid hemorrhages, and edema (13–15). 
Increased cathepsin B expression has long been known to result 
from ischemia with brain activity increasing about two- and 
fivefold relative to controls at 2 and 5 days after injury in ischemic 
rat and monkey models, respectively (107–109). Similarly, in an 
aneurysm model, cathepsin B mRNA increased about fivefold 
and activity increased about twofold 3  months after aneurysm 
induction relative to controls (104). In a subarachnoid hemor-
rhage model, cathepsin B protein increased about 3.5-fold at 2 and 
3 days after hemorrhage induction relative to controls (102, 103). 
Cathepsin B protein levels are increased in chronic hypertension 
brain edema (105) and acute ischemic edema models (106). Thus, 
cathepsin B expression is also increased in important vascular 
pathologies caused by TBI.
Brain infections are a common TBI complication (18) and 
cathepsin B levels are greatly increased in meningitis and sepsis 
animal models (42, 113, 114). Moreover, aseptic inflammation 
and pain are major factors in TBI (16), and cathepsin B is elevated 
in aseptic inflammatory and pain animal models (115, 116).
Finally, as discussed above, TBI is a risk factor for several 
neurodegenerative diseases. Cathepsin B mRNA is elevated 
3.5-fold relative to controls in spinal cord samples from an 
ALS mouse model (117). Moreover, an ALS meta-analysis 
of the literature identified cathepsin B as repeatedly up-
regulated in ALS patients and mouse models (121). TBI 
causes excitotoxicity (19) and cathepsin B protein levels are 
elevated in excitotoxicity animal models of recurring epilepsy 
and Huntington’s chorea (112, 122). Furthermore, cathepsin B 
mRNA is increased in the transgenic AD 5Xfamilial AD (FAD) 
mouse model, which expresses human amyloid precursor pro-
tein (APP) containing three familial AD mutations and human 
presenilin 1 (PSN1) containing two familial mutations (119). 
Cathepsin B protein is also increased by 50% in the cortex 
and hippocampus of the APPSwe/PS1 model, which expresses 
human APP containing the Swedish (Swe) FAD mutation and 
PS1 with FAD mutations, relative to controls (120). Thus, 
cathepsin B is elevated in several neurodegenerative animal 
models associated with TBI.
Clinical Data: Cathepsin B Regulation in  
TBi-Related injuries
Short-Term Changes in Cathepsin B Observed in 
Polytrauma and Aneurysm
We are not aware of any clinical studies on acute cathepsin B 
regulation due to TBI, but non-brain polytrauma patients show 
increases in plasma cathepsin B activity during the first day after 
trauma, which subsequently falls to moderately elevated levels by 
the third day, and remains roughly at that level for up to 2 weeks. 
Importantly, the increase in plasma cathepsin B activity corre-
lates with the severity of injury. Patients with a sixfold increase 
in plasma cathepsin B activity 1 day post-trauma subsequently 
developed fatal or reversible multiple organ failure, whereas those 
who had only a threefold increase, at the same day, did not display 
organ failure (123, 124).
Moreover, in human cerebral aneurysm tissue, cathepsin B is 
highly expressed in the endothelial cell layer and the media in the 
aneurysmal walls in contrast to control artery tissue where it is 
barely expressed at all (104). Thus, cathepsin B expression appears 
to be significantly increased as a result of TBI type injuries in man.
Long-Term Changes in Cathepsin B in Chronic 
Inflammatory Conditions
Patients having the chronic inflammatory neurological diseases 
Guillain–Barre syndrome, chronic demyelinating polyneu-
ropathy, or MS have higher cerebrospinal fluid (CSF) cathepsin 
B activity levels than controls (125, 126). Cathepsin B mRNA 
levels in ALS postmortem spinal cord tissue has been shown to 
be about 2- and 3.3-fold higher than that of non-neurological 
age-matched controls (117, 127) and cathepsin B protein expres-
sion is increased and has an abnormal distribution, especially in 
the anterior horn, relative to controls (128). AD brain autopsy 
samples show a high cathepsin B protein expression, especially 
near pathological amyloid plaque brain deposits, relative to 
age-matched control samples (129). Moreover, AD patients have 
a significant 50% higher plasma and serum cathepsin B protein 
level than age-matched control samples (120, 130) and higher 
serum cathepsin B levels in AD patients strongly correlates with 
reduced cognitive ability (120). Interestingly, cathepsin B protein 
levels in peripheral blood lymphocytes and monocytes from AD 
patients are about 50% lower than those from controls (85) and 
that, taken together with the plasma and serum data, suggest that 
cathepsin B may redistribute from peripheral blood cells to the 
serum/plasma compartment in AD patients. CSF cathepsin B 
studies in AD patients have shown a significant increase (131) 
by proteomic analysis and no significant difference but a trend 
toward higher levels by ELISA and Western blot analysis relative 
to controls (130, 132).
In the peripheral inflammatory conditions of RA and osteo-
arthritis (OA) synovial cells and chondrocytes have increased 
cathepsin B mRNA levels and cathepsin B protein secretion 
relative to controls (133, 134). Furthermore, in patients with 
inflammatory bowel disease, cathepsin B is up-regulated in areas 
of tissue damage and mucosal ulceration (135).
FiGURe 2 | Cathepsin B gene deletion improves neuromotor deficits 
caused by TBi. Mice with knockout of the cathepsin B gene were assessed 
for TBI-caused neuromotor deficits. Four groups of mice were assessed: 
sham wild-type (Sham WT), sham cathepsin B gene knockout (Sham KO), TBI 
WT, and TBI cathepsin B gene knockout (TBI KO). TBI was modeled by 
controlled cortical impact (CCI) and mice were subjected to rotarod behavioral 
neuromotor evaluations before and 7 days after TBI trauma. Longer latency 
times indicate better neuromotor function. Sham WT and Sham KO animals 
were not surgically treated the same as TBI animals and were not traumatized. 
Significantly, knockout of the cathepsin B gene resulted in improved 
neuromotor defictis and a shorter recovery period compared to TBI WT mice 
(mean ± SEM, Bonferroni’s multiple comparison test P < 0.05, N = 10 
animals/group, *TBI WT vs. Sham WT, ^TBI KO vs. Sham KO, and #TBI WT 
vs. TBI KO) (48). Data from cited publication adapted for graphic display.
TABLe 2 | Animals lacking the cathepsin B gene are healthy.
Behavior Morphology/
histology
Fertility Biomarkers Reference
nd nd nd No effect on MHC 
antigen processing
(59)
No 
apparent 
behavioral 
deficits
Indistinguishable 
from wild-type 
mice
Normal Normal (136)
nd nd nd Reduced 
thyroglobulin 
solubilization and 
degradation
(137)
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Cathepsin B Gene Knockout improves 
Deficits in TBi and TBi-Related Animal 
Models
Cathepsin B Knockout Mice are Healthy
The health of cathepsin B gene knockout mice is maintained and 
generally indistinguishable from normal littermates in behavior, 
histology, and fertility (136), as shown by data summarized in 
Table 2. The only reported difference is a decrease in thyroglobu-
lin (Tg) solubilization (137) but this does not appear to cause a 
significant phenotypic or behavioral effect. The normal health of 
mice lacking cathepsin B implicates that pharmacologic inhibi-
tion of cathepsin B will likely be generally safe.
TBi Mice with Cathepsin B Knockout: improved 
Deficits and Pathology
Table 3 summarizes the data on the effect of deleting the cathep-
sin B gene in TBI models and shows that the deletion improves 
behavior, pathology, and neuronal cell survival (48). Figure  2 
shows that deleting the cathepsin B gene reduces the severity and 
duration of the neuromotor dysfunction that occurs during the 
week following trauma with the deficient mice suffering about 
half the dysfunction of wild-type (wt) mice 1  day after trauma 
and regaining normal function, whereas the wt mice remain 
significantly impaired 1 week after trauma. Figures 3 and 4 show 
that 1 week after trauma, cathepsin B gene-deficient animals have 
about one-third the brain lesion volume of wt animals and no hip-
pocampal neuronal cell loss, whereas wt mice suffered a 60% loss 
relative to the sham animals. As discussed below, apoptosis con-
tributes to TBI-induced cell death and the pro-apoptotic cell death 
biomarker, Bax, is elevated 1 day post-trauma in wt mice, but not 
in cathepsin B gene knockout mice relative to sham controls. The 
clear conclusion is that cathepsin B is a significant contributor to 
the behavioral dysfunction and neuronal cell loss that follows TBI.
TBi-Related Models with Cathepsin B Knockout 
Show improved Outcomes
Deleting the cathepsin B gene produces significant beneficial out-
comes in TBI-related pathological animal models and includes 
surgery, epilepsy, AD, inflammation, pain, and cytokine cell death 
models. Deletion of both cathepsin B and cathepsin S improves 
the outcomes in an MS model (see Table 3).
Surgery Model
In the traumatic post-operative ileus surgery model, deleting the 
cathepsin B gene results in significantly less ECM breakdown and 
collagen-type IV loss than occurs in wt animals in that model 
(101). Cathepsin B, therefore, is likely a key target to preventing 
ECM breakdown resulting from TBI.
Epilepsy Model
TBI increases the risk of epilepsy (23), which can result in neuro-
excitotoxicity. Deleting the cathepsin B gene in the Unverricht–
Lundborg progressive myoclonus epilepsy model prevents about 
90% of the apoptotic neuronal cell death that usually occurs 
in these animals. (138). Thus, cathepsin B is also likely to be 
an important target for preventing the TBI neuroexcitotoxity-
induced cell death.
Alzheimer’s Disease Model
TBI increases the risk of AD (22), which is thought to result 
from the abnormal accumulation of brain amyloid-β (Aβ). In 
transgenic AD mice expressing human APP containing the 
human wt β-secretase site, which is what most AD patients have, 
deleting the cathepsin B gene improves memory deficits and 
reduces the brain amyloid plaque, which is a neuropathologi-
cal hallmark of AD, that develop in these animals (140, 141). 
That deletion in such transgenic animals also reduces brain 
Aβ(1-40/42) and the pernicious post-translationally modified 
pyroglutamate (pGlu) Aβ(3-40/42) forms (139–141), which are 
thought to be particularly neurotoxic among Aβ peptide species 
(147). These and other data (148–150) show that cathepsin B 
has wt β-secretase activity, which cleaves APP and can produce 
Aβ species.
On the other hand, cathepsin B gene deletion in transgenic 
models expressing APP containing the Swe FAD mutation does 
FiGURe 3 | Cathepsin B gene deletion reduces brain tissue lesions 
caused by TBi. At 7 days post-TBI (mice receiving CCI TBI), mouse brains 
were evaluated to determine the brain volume loss (Lesion Volume) at the 
impact site. (A) Quantitative image analysis of brain sections showed that 
cathepsin B gene deletion minimized brain tissue loss. The Sham WT and 
Sham KO animals had no loss whereas the TBI WT mice had significant loss, 
but the TBI KO mice had roughly one-third the loss suffered by the TBI WT 
mice. Representative micrographs from the brains of Sham WT, Sham KO, TBI 
WT, and TBI KO animals are shown in (B–e), respectively. (mean ± SEM, 
Bonferroni’s multiple comparison test P < 0.05, N = 10 animals/group, *TBI 
WT vs. Sham WT, Sham KO, and TBI KO, and #TBI KO vs. Sham WT and 
Sham KO) (48). Data from cited publication adapted for graphic display.
FiGURe 4 | Cathepsin B gene deletion reduces neuronal loss after TBi. 
Quantitative image analyses of brain sections evaluated for Lesion Volume were 
also analyzed for neuronal cell density in the CA3 region of the hippocampus, 
which is distal to the impact site. (A) TBI WT, but not TBI KO, mice had lower 
neuronal density than Sham WT and Sham KO animals. Thus, cathepsin B 
knockout resulted in reduced neuronal loss. Representative micrographs from 
the brains of Sham WT, Sham KO, TBI WT, and TBI KO animals are shown in 
(B–e), respectively (mean ± SEM, Bonferroni’s multiple comparison test 
P < 0.05, N = 10 animals/group, * TBI WT vs. Sham WT, Sham KO and TBI 
KO) (48). Data from cited publication adapted for graphic display.
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not significantly affect Aβ and increases amyloid plaque (142). The 
Swe mutation alters the amino acid sequence at the β-secretase 
site, which destroys the cathepsin B target sequence and thus 
cathespsin B does not cleave this form of APP (151). However, 
the Swe FAD mutation occurs in only one extended family, 
whereas most people express normal APPwt. Thus, cathepsin B 
gene deletion reduces Aβ in models mimicking the β-secretase 
activity occurring in most humans. Given that, the inhibition of 
cathepsin B may be able to prevent the increased brain Aβ, which 
also occurs after TBI (152, 153).
Inflammation and Inflammatory Pain Models
TBI induces microglia activation and inflammation, which can 
occur for a prolonged period after trauma and can cause neu-
ronal cell death (154). Moreover, TBI causes inflammatory pain 
(16) and increases the proinflammatory cytokines interleukin-1β 
(IL-1β), and interleukin-18 (IL-18), which are related to pain 
(155, 156). These cytokines are controlled by caspase 1 in protein 
complexes known as inflammasomes, which are also activated 
by TBI (157).  Administering Freund’s adjuvant to animals, in 
the peripheral tissues, induces inflammatory pain and inflam-
mation, but doing so to cathepsin B gene-deficient mice results 
in significantly less pain (tactile allodynia), less IL-1β, IL-18, 
caspase 1 activation, and less inflammasome activation than 
occurs in wt animals (115, 143). Microglia phagocytosis of fibril-
lar Aβ or chromogranin A (CGA) causes microglia activation 
and cathepsin B expression leading to inflammasome formation 
and production of IL-1β, and activated caspase 1. These micro-
glia responses do not occur in cathepsin B-deficient mice (116, 
158). These data suggest that cathepsin B is also a critical target 
for reducing CNS inflammation and inflammatory pain caused 
by TBI.
TABLe 3 | Cathepsin B gene deletion improves deficits of TBi and  
TBi-related animal models.
Model Cathepsin B gene deletion effect Reference
Behavior Pathology Biomarkers
Trauma TBI ↓ 
Neuromotor 
dysfunction
Brain ↓ Brain bax (48)
↓ Lesion vol; 
Neuron death
Trauma surgery 
post-op ileus
nd ↓ ECM 
destruction
↓ ECM 
collagen IV
(101)
Neuroexcitatory 
epilepsy
No effect on 
seizures
↓ Brain 
neuron death
nd (138)
Neurodegeneration 
AD transgenic 
human APPwt
nd nd Brain
↓ Aβ 
(1-40/42); 
CTFβ
↑ sAPPα
(139)
Neurodegeneration 
disease AD 
transgenic human 
APPLon
↓ Memory 
deficits
↓ Brain Aβ 
plaque
Brain
↓ Aβ(1-40/42); 
CTFβ
↑ sAPPα
(140)
↓ Brain pGlu- 
Aβ plaque
↓ Brain pGlu- 
Aβ(3-40/42)
(141)
Neurodegeneration 
AD transgenic 
human APPSwe
nd ↑ Brain 
plaque
No significant 
change brain 
Aβ (1-X/42)
(142)
Neurodegeneration 
fibrial Aβ, 
chromogranin 
microglia challenge
nd nd ↓ microglia 
IL-1β, 
caspase 1
(143)
Inflammation/pain ↓ Chronic 
inflammatory 
pain
↓ Activated 
microglia
Brain
↓ mIL-1β; 
mIL-18; Cox2
(115)
Aging inflammation nd nd ↓ Brain IL-1β (116)
LPS-induced 
inflammation
nd nd Macrophages
↓ TNFα 
secretion
(144)
TNFα challenged 
hepatocytes
nd nd Hepatocytes
↓ caspase 2
↓ mito cyt c
(145)
Neuro-degeneration 
MS EAE cathepsin 
B and S double 
knockout
nd Improved 
clinical score
↓ spinal cord 
leukocyte 
infiltration
↑ age of onset
↓ Immune 
cell markers 
(MHC-II, 
CD69 CD4+ 
cells) 
(146)
nd, not done; ECM, extracellular matrix; mIL-1β, mature interleukin-1β; mIL-18, mature 
interleukin-18β; mito cyt c, mitochondrial cytochrome c; ALT, alanine aminotransferase; 
HSC, hepatic stellar cells; APPwt, wild-type amyloid precursor protein; APPLon, 
amyloid precursor protein containing the London mutation, CTFβ, C-terminal β-
secretase fragment; pyrogluAβ, pyroglutamate Aβ; EAE, experimental autoimmune 
encephalomyelitis. Blue and tan colors indicate significant effects on behavior and 
pathology, respectively, by cathepsin B gene deletion.
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to TNFα-induced liver damage and hepatocyte apoptotic cell 
death and have reduced TNFα-induced caspase activation 
and mitochondrial cytochrome c (cyt c) release, which are key 
apoptotic proteins (145, 161). More recently, macrophages from 
cathepsin B-deficient mice treated with lipopolysaccharide (LPS), 
which induces an intense TNFα response, were shown to secrete 
50% less TNFα than wt macrophages (144). Thus, cathepsin B is 
an important target for preventing the TNFα-induced cell death 
that occurs as a result of TBI.
Cathepsin B and Cathepsin S Knockouts have 
Improved Outcomes in Multiple Sclerosis Model
TBI has been associated with an increased risk of subsequent MS 
development in the Chinese population (24). In an experimental 
autoimmune encephalomyelitis (EAE) mouse model of MS, dele-
tion of cathepsin B or cathepsin S gene alone had no effect but 
deletion of both cathepsin B and S genes improved clinical scores 
and significantly delayed age of disease onset relative to sufficient 
animals (146).
Summary: Cathepsin B Knockout has Little 
effect in Development but has Major 
Neuroprotective effects on TBi and TBi-Related 
injuries
The cathepsin B gene knockout mice show little or no adverse 
impact on normal functions, but have major beneficial effects in 
TBI, including reductions in neuromotor deficits, brain pathol-
ogy, and neuronal cell death. Cathepsin B deficiency produces 
substantial improvement in important pathologies related to 
TBI, including reductions in ECM breakdown, neuroexcitatory-
induced cell death, inflammation, inflammatory pain, TNFα-
induced cell death, Aβ levels, and memory deficits.
It is likely that the absence of developmental defects associ-
ated with cathepsin B deficiency is due to redundant protease 
specificity of the closely related protease, cathepsin L, which 
can substitute for the normal function of cathepsin B. Evidence 
in support of this hypothesis is that cathepsin B and L double 
knockouts are lethal and have profound neurological abnormali-
ties (162, 163). Thus, some cysteine cathepsin proteolytic activity 
is required for fetal development. This has implications, which 
are discussed below (7.5), for the therapeutic development of 
compounds.
The large volume of data from the cathepsin B knockout mice 
indicates that this protease is central to many different pathologi-
cal processes. Many benefits occur from this deficiency, leading 
to the compelling conclusion that cathepsin B inhibition is a 
promising therapeutic approach for TBI.
Mechanisms of Cathepsin B Regulation in 
Normal Compared to TBi injury Conditions
Neurobiology of Normal Cathepsin B Regulation
Cathepsin B Distribution
Tissue distribution of cathepsin B
Early studies demonstrated that cathepsin B is present in human 
tissues throughout the body (164), but that the concentration 
TNFα Models
Tumor necrosis factor alpha (TNFα) is a cytokine that induces 
a cytoplasmic molecular cascade including cathepsin B release 
from lysosomes and apoptotic cell death (159) and TBI increases 
brain TNFα (160). Cathepsin B gene-deficient mice are resistant 
FiGURe 5 | Cathepsin B protein concentration vary among tissues. 
The levels of mature cathepsin B concentrations are shown from rat tissues 
(mean ± SD displayed, N = 4 analyses, means significantly different, ANOVA, 
p < 0.0001) (165). Data from the cited publication and adapted to graphic 
display and analyzed for variance.
FiGURe 6 | Cathepsin B expression occurs in selected regions of the 
brain. (A,B) are micrographs of the same coronal mouse brain section and 
show tissue structure and cathepsin B mRNA expression, respectively. In (A), 
the section is nissl stained, which highlights neurons as dark blue. In (B), in situ 
hybridization of sections with antisense mRNA to cathepsin B illustrates the 
brain regions of cathepsin B mRNA expression. Hotter colors, such as yellow 
and red, signify high expression, cooler colors, such as green and blue, 
indicate low expression, and black indicates undetectable expression. A 
comparison of the two micrographs shows that cathepsin B is intensely 
expressed in the hippocampal neuronal cell layer (arrows) and in the cortex 
(box). Figures taken from the Allen Brain Institute web site http://www.
brain-map.org/.
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varied as exemplified in Figure  5, which shows the cathepsin 
B concentrations in selected rat tissues (165). Moreover, these 
studies also established that cathepsin B concentrations varied 
among cell types with rat peripheral macrophages having 
cathepsin B concentrations that are 33, 50, and 400 times higher 
than lymphocytes, neutrophils, and erythrocytes, respectively, 
and that immunologically activating macrophages causes a fur-
ther sixfold increase in cathepsin B levels (165). The cathepsin 
B variation among the different tissues and cells suggests that 
cathepsin B is differentially expressed among the tissues and has 
specialized functions in addition to lysosomal protein degrada-
tion (165, 166).
An on-line human protein tissue atlas (167) also shows that 
cathepsin B is widely expressed in the body with cathepsin B 
mRNA found in all and protein detected in 80% of the tissues 
(http://www.proteinatlas.org/). Moreover, the amount of cathep-
sin B expression varies among different tissues and cell types.
Brain cathepsin B
Early immuno-microscopic analysis showed that human brain 
contains cathepsin B and it is concentrated in neuronal cell types, 
especially in the hippocampus (164, 168–171). By contrast, only 
a few glia cells in normal brain were seen to contain significant 
amounts of cathepsin B (168). A similar intense neuronal cell 
staining was also seen in rodent brain, especially in the pyramidal 
cells of the cortex, large neurocytes of the septal region, many 
hippocampal neurons, and magnocellular nerve cells of the 
hypothalamus (97, 168, 172, 173).
Early cathepsin B mRNA analysis of rat brain also showed 
cathepsin B expression concentrated in neurons (174) and more 
recent data confirm this distribution. Figure 6 shows cathepsin 
B mRNA expression and histological images in a normal mouse 
brain section. Cathepsin B is selectively and intensely expressed 
in the hippocampal neuronal cell layer and in the cortex. The 
images were obtained from the Allen Brain Institute web site. A 
comparison of the papain-like cysteine protease mRNA expres-
sion levels in that section shows that cathepsin B is expressed the 
most followed by cathepsin L with all others expressed at very low 
levels or not at all.
CSF and plasma cathepsin B
Table 4 shows the human CSF and plasma cathepsin B concentra-
tions (130). The plasma concentration is about 14 times greater 
than that in the CSF. Human and rat CSF cathepsin B concentra-
tions increase with age (175, 176).
TABLe 4 | Human CSF and plasma cathepsin B concentrations.
Sample (number 
of individuals)
Measured 
concentrationc  
ng/mL 
estimated molar 
concentrationd 
μmol/L
Reference
CSF (118)a 8.4 3.36 × 10−4 (175)
CSF (28)b 9.6 ± 3.4 3.84 × 10−4 (130)
Plasma (28)b 134.3 ± 71.3 53.7 × 10−4 (130)
aSurgery patients, 21–82 years old, mean age 65 years, predominately male.
bHealthy volunteers, mean age 63.9 ± 6.2 years old, predominately female.
cValue reported by reference, mean ± SD.
dEstimated value to facilitate comparison with Table 5 data assuming a cathepsin B 
molecular weight of 25,000.
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Subcellular Organelle Compartments and Functions
Lysosomes
A major destination for cathepsin B is the lysosome, the name of 
which is from the Greek lysis: loosen and soma: body. Christian 
de Duve discovered that these subcellular structures were 
recycling centers in which unwanted proteins are dismantled to 
their amino acid building blocks for recycling into new proteins 
for which he received the 1974 Nobel Prize in Physiology or 
Medicine (177). Lysosomes are membrane-bound compartments 
present within neurons and cells in the cytosol but outside the 
nucleus. Lysosomes sequester cytosolic proteins at a rate of no 
more than 4% per hour but rapidly digest those with a half-life 
of less than 10 min, which means that the proteolytic capability 
is at least 20 times that of the highest substrate uptake (178, 179). 
This rapid hydrolysis is due to the high lysosomal protease con-
centration, which can be more than 1 mM (180), present at a pH 
significantly more acidic than the cytosol of the cell (discussed 
in the section below on pH and cystatin). Lysosomal cathepsins 
L, B, and S account for roughly 50% of the total bulk protein 
degradation (181) and the lysosomal cathepsin B concentration 
is about 330  ng/mg protein (87). Thus, cathepsin B is a major 
and key component of lysosomes, which are powerful proteolytic 
machines containing high concentrations of proteases capable of 
rapid digestion of large amounts of proteins.
In addition to digestive lysosomes, cathepsin B is also traf-
ficked to secretory lysosomes, which release their contents to the 
extracellular environment in response to a triggering event. These 
lysosomes are primarily found in immunological cell types and 
brain astrocytes (182, 183). Containment in and release from 
secretory lysosomes to the extracellular space allows the cell to 
safely export the proteolytic capability of cathepsin B and other 
lysosomal proteases as needed. For example, glia cells secrete 
cathepsin B in response to neurotoxin exposure via secretory 
lysosomes (184).
But lysosomal cathepsin B can also cleave proteins at specific 
recognition sites to produce protein fragments having important 
biological activities. For example, cathepsin B cleaves in the lyso-
some non-phosphorylated myristoylated alanine-rich C kinase 
substrate (MARCKS), which is the primary substrate for protein 
kinase C (PKC), to prevent phosphorylation and thereby control 
cell morphology and motility (185–187). In the thyroid gland, 
cathepsin B traffics via secretory lysosomes to the extracellular 
lumen of the thyroid follicles (188) where it cleaves Tg and solu-
bilizes it (137).
Autophagosomes
Autophagosomes are structures in which unnecessary or dys-
functional cellular components are degraded. Lysosomes fuse 
with autophagosomes to provide the proteases needed for that 
degradation and cathepsin B is a key protease in autophagy 
catabolism (189).
Regulated secretory vesicles
Lysosomes are not the only subcellular destination for cathepsin 
B (190). It is also found in regulated secretory vesicles of cells, 
which secrete large amounts of enzymes, hormones, or neuro-
transmitters to the extracellular space. Neurons and endocrine 
cells are such cells and are unique in having a RSP (regulated 
secretory pathway), in which material to be exported is densely 
stored in regulated secretory vesicles that discharge their con-
tents out of the cell in response to a triggering signal (191). In 
pancreatic acinar cells, more cathepsin B is present in the RSP 
than lysosomes, and in the RSP cathepsin B cleaves trypsinogen 
to activate trypsin (192, 193). Cathepsin B is in the RSP of β-cells 
of mouse pancreatic islets where it co-localizes with insulin 
(194). Cathepsin B is found in dense secretory granules of kidney 
juxtaglomerular cells (195). In bovine adrenal chromaffin cells, 
cathepsin B is present in the RSP where it proteolytically cleaves 
wt APP to produce Aβ (148). As in the lysosome, cathepsin B is 
physically separated from the cytosol by membranes of secretory 
vesicles within the RSP.
Summary: Cathepsin B is Normally Packaged into Discrete 
Subcellular Organelles
From a TBI point of view, the important point is that cathepsin B is 
normally mostly contained within subcellular organelles and this 
compartmentalization allows the cell to safely utilize the proteo-
lytic powers of cathepsin B without damaging the cell structure. 
As discussed below, that segregation is compromised after brain 
trauma leading to cathepsin B-induced injury and pathology.
pH and Cystatin Control of Cathepsin B and Cysteine 
Protease Activity
pH regulation
Cathepsin B zymogen is activated by cathepsins in the lysosome/
endosome compartments where they have optimum efficiency 
in the acidic environment of about pH 5.0 and the papain-like 
cysteine proteases require a reducing environment (67). The 
lysosomal membrane contains molecular pumps, which create 
that environment inside the lysosome and maintain it against the 
neutral pH 7.4 of the cytosol.
Cathepsin B’s enzymatic activity is reduced at neutral pH 
(196). For example, cathepsin B cleaves trypsinogen at pH 4.0 
to 5.2, but not at a higher pH (192). Nonetheless, cathepsin B 
retains significant activity at the neutral pH of the cell cytosol 
after translocation from the lysosomes (197). Cathepsin B has 
a complex pH dependency among its endopeptidase and exo-
peptidase activities. In  vitro, cathepsin B exopeptidase activity 
TABLe 5 | Human CSF and plasma cystatin C concentrations.
Sample (number of 
individuals)
Measured 
concentrationb μmol/L
Reference
CSF (28)a 5.6 ± 1.6 (130)
Plasma (28)a 0.9 ± 0.2 (130)
aHealthy volunteers, mean age 63.9 ± 6.2 years old, predominately female.
bValue reported by reference, mean ± SD.
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predominates below pH of 5.5 and endopeptidase activity prevails 
above pH 5.5 (198). Glycosaminogycans bind to cathepsin B to 
stabilize its structure and preserve its endopeptidase activity in 
the neutral pH of the cytosol (199). In comparison, cathepsin B is 
much more stable than cathepsin L at neutral pH (200). The key 
point is that cathepsin B retains significant enzymatic activity at 
pH 7.4 and thus can inflict major damage when set loose in the 
cytosol or the extracellular environment.
Cystatin regulation
The endogenous cystatin proteins are probably the most important 
means of controlling cytosolic and extracellular cysteine protease 
activity (200); cystatins are emergency inhibitors that neutralize 
cysteine proteases, which escape from the lysosomes (70, 201) 
and are of high importance in TBI. Type 1 cystatins are primarily 
intracellular proteins and type 2 cystatins are found in extracellular 
fluids. Cystatin C, a type 2 cystatin, is the controlling inhibitor for 
cathepsin B in human extracellular fluids, including CSF, blood 
plasma, synovial fluid, milk, saliva, seminal fluid, amniotic fluid, 
and tears (202). The inhibitor concentrations vary among the flu-
ids but cystatin C has the highest CSF concentration of any of the 
endogenous inhibitors and is the most potent cathepsin B inhibitor 
of the endogenous inhibitors in those fluids. The cathepsin B activ-
ity half-life (t1/2) when exposed to cystatin C at the concentrations 
in the extracellular fluids is less than a second (202).
Table  5 shows the human CSF and plasma cystatin C con-
centrations (203). The CSF cystatin C concentration is about 5.5 
times higher than that in plasma. Comparing the molar concen-
trations with those for cathepsin B in Table 4 shows that the CSF 
and plasma cystatin C concentrations are 16,000 and 170-fold 
greater than that of CSF and plasma cathepsin B concentrations, 
respectively. The high cystatin C to cathepsin B ratios show that 
inhibiting cathepsin B activity in these compartments is critical, 
especially in the brain. TBI increases cystatin C and an increase in 
cystatin C soon after trauma is associated with reduced neuronal 
cell damage (97).
Lysosomal Leakage of Cathepsin B
Lysosomal release of cathepsin B to the cytoplasm can overwhelm 
the normal controls and cause significant damage. The potential 
of the lysosome as a “suicide bag” capable of killing the cell if its 
protease contents escape to cytosol and other compartments has 
long been recognized (204).
TBI Causes Lysosomal Leakage of Cathepsin B
Trauma causes lysosomal cathepsin B leakage to the cytosol in 
animal models. In normal brain, immunostaining shows that 
all neurons have a punctate cathepsin B distribution, which 
reflects its lysosomal location, but after TBI injury many neu-
rons display diffuse staining throughout the neuron cell body 
showing that cathepsin B has escaped the lysosome contain-
ment (97, 205).
Controlled cell shear of primary neuronal cell cultures mimics 
TBI damage and causes neuronal cell death (206). Cytosolic and 
lysosome fractions from sheared cells have elevated and reduced 
cathepsin B, respectively, which is consistent with lysosomal 
cathepsin B leakage. Sheared neurons are more likely to die than 
unsheared neurons and treatment with the membrane sealant 
Poloxamer 188 prevents leakage and reduces cell death in sheared 
cells (206). Moreover, Poloxamer 188 treatment in TBI CCI and 
ischemic mouse models reduces neuronal cell death (207, 208).
TBI-Related Injuries also Cause Lysosomal Leakage 
of Cathepsin B
Ischemia causes the rearrangement of cathepsin B from the lys-
osomes to the cytoplasm in non-human primate brain neurons 
(108). Niemann–Pick disease Type C is a genetic lysosomal 
storage disease, and in mouse models of this disease, cathepsin 
B leaks out of lysosomes in neurons of the cerebellum (209). In 
epilepsy animal models, seizures result in translocation of lysoso-
mal cathepsin B to the cell body and nucleus (210). ALS autopsy 
samples show that cathepsin B is diffusely distributed within 
degenerative neurons (128). In nerve cells of brain autopsy tissue 
from AD and Parkinson’s dementia of Guam and senile dementia, 
but not age-matched controls, cathepsin B is found in neurites 
and dendrites and in the pathological neurofibrillary tangles and 
plaque structures (129, 170, 171). And in AD and Parkinson’s 
cell culture models, Aβ(1-42) and α-synuclein cause lysosomal 
leakage of cathepsin B into the cytoplasm (211–213).
Mechanisms of Lysosomal Leakage of Cathepsin B
Molecular mechanisms of lysosomal leakage have been sum-
marized in an excellent recent review (214). Many of the mecha-
nisms were discovered in abnormal cancer cells and those are not 
discussed because it is not clear how relevant they are to normal 
neurons.
Unique to trauma is that mechanical force directly breaks 
membranes and is likely the primary cause of lysosomal rupture 
at the site of injury. These forces can rapidly damage large amounts 
of tissue and cause the release of significant amounts of proteases, 
which autodigest the brain tissue.
Ischemic monkey and rat animal model data generated the 
“calpain/cathepsin” neuronal cell death hypothesis, which is 
based on lysosomal cathepsin B leakage (215, 216). Injury 
induces calcium ion entry into neurons causing μ-calpain activa-
tion, which indirectly permeabilizes lysosomal membranes. Heat 
shock protein 70.1 (HSP 70.1) normally stabilizes lysosomal 
membranes by binding to them via endolysosomal phospho-
lipid bis(monoacylglycero)phosphate (BMP) and enhances 
membrane stabilizing acid sphingomylinase (ASM) activity. 
Ischemia decreases HSP 70.1 and BMP and increases oxidized 
HSP 70.1, which is cleaved by activated μ-calpain, and those 
changes decrease ASM and together cause lysosomal membrane 
 permeability, the release of lysosomal cysteine proteases, and cell 
death (217).
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Cathepsin B also contributes to lysosomal leakage as illus-
trated by the reduced lysosomal leakage that occurs in cathepsin 
B-deficient hepatocytes vs. wt cells responding to TNFα toxicity 
(218). The fact that trauma causes increased cathepsin B and 
TNFα suggests that cathepsin B may contribute to lysosomal 
leakage in TBI.
Free radical formation can also contribute to lysosomal mem-
brane breakdown. TBI pathology causes a pronounced increase 
in free radicals and oxidative brain damage (219, 220). The 
free radicals enter lysosomes, react with iron to form hydroxyl 
radicals, which react with lysosomal membrane components 
thereby destabilize the lysosomal membrane and cause it to leak 
(221). Treating subarachnoid hemorrhage models with iron 
chelators deferoxamine or α-lipoic acid protected lysosomal 
membranes and prevented cathepsin B leakage, which correlated 
with improved outcomes, such as reductions in brain edema, 
blood–brain-barrier impairment, and neuronal cell death, and 
also improved behavioral deficits (102, 103).
TBi-induced Lysosomal Leakage Causes 
Necrotic and Apoptotic Cell Death, 
inflammation, and Axonal Damage
Necrotic Cell Death
The extent to which the lysosomal membrane is disrupted by 
an injury is a key driver in determining the resulting pathology. 
A frank rupture is generally thought to result in necrotic cell 
death whereas a lesser amount of leakage causes apoptotic cell 
death (222, 223). The molecular machinery causing necrotic and 
apoptotic death is complex and diverse and has been the subject 
of several reviews (214, 222, 224).
The molecular mechanisms by which cathepsin B participates 
in necrotic cell death are yet to be fully understood presum-
ably because of the difficultly in studying the rapidly occurring 
multiplicity of reactions that lead to necrotic death. But one 
mechanism by which lysosomal rupture causes necrotic cell death 
is through activation of the inflammasome receptor NOD-like 
receptor (NLR) family pyrin domain-containing 3 (NLRP3) by 
cathepsin release into the cytoplasm (225). As discussed below, 
NLRP3 activation by cytosolic cathepsin B is also central to the 
inflammatory response caused by lysosome leakage.
Apoptotic Cell Death
Apoptotic cell death cascade occurs following trauma and cath-
epsin B is a key component of that cascade (94, 98). TNFα is 
elevated after trauma and it is an extracellular cell death signal 
that sets into motion intracellular molecular events that ulti-
mately lead to cell death. The pathway includes TNFα binding 
to tumor necrosis factor receptor 1 (TNFR1) causing cytosolic 
activation of caspase 8, Bid cleavage to t-Bid, and polymerization 
of BAX, which forms mitochondrial membrane pores causing 
mitochondrial leakage to the cytoplasm of cytochrome C (cyt 
c), which activates the apoptotic initiator caspase 9 causing acti-
vation of the executioner caspase 3 (226). Direct evidence that 
cathepsin B contributes to this pathway in TBI comes from data 
showing that deleting the cathepsin B gene in a TBI mouse model 
blocks BAX activation following trauma (48). E64d, which is an 
inhibitor of cathepsin B and other papain-like cysteine proteases 
and calpains 1 and 2 discussed below (see section on ‘E64, E64d, 
and E64c cysteine protease inhibitors’), administered to TBI 
mouse models reduced proapoptotic proteins t-Bid, BAX, and 
cytosolic cyt c, and activated caspase 3 and antiapoptotic protein 
Bcl-2 (94). The effects of E64d on reducing apoptotic cell death 
are likely primarily due to cathepsin B inhibition because E64d 
given to cathepsin B knockout mice produced no additional 
reduction on BAX levels after trauma than that obtained in 
cathepsin B gene deletion mice given the vehicle solution (48). 
Thus, cathepsin B is an important component to TBI-induced 
TNFα cell death.
Studies in hepatocytes from cathepsin B knockout animals 
that show the TNFα-induced lysosomal leakage of cathepsin 
B to the cytosol cleaves Bid and activates caspase 2, which 
facilitate mitochondrial release of cyt c to the cytosol and that 
triggers caspase apoptotic cell death (145, 161). Treatment 
of normal human blood lymphocytes with antithymocyte 
antibodies also results in lysosomal cathepsin B leakage to the 
cytosol and apoptotic cell death by an undefined mechanism 
that does not involve the intrinsic mitochondrial cyt c pathway 
(227). Unraveling the exact means by which cathepsin B func-
tions in the TBI-induced death pathway will be an exciting area 
of future research.
Inflammation
Cathepsin B is secreted by inflamed microglia and induces 
apoptosis. Trauma to the CNS causes diverse inflammatory cells 
expressing high levels of cathepsin B, which include microglia 
and macrophages, to gather at a site of injury (100). Inflammation 
induced by CGA in primary microglia cultures causes those cells 
to secrete cathepsin B, which induces apoptotic cell death in pri-
mary granule neuronal cultures possibly by executioner caspase 3 
activation (228). Thus, cathepsin B in the extracellular space can 
induce neuronal apoptotic cell death.
TBI can cause massive cellular and cytokine inflammatory 
responses that focus on cathepsin B as the center of TBI-caused 
damages. As discussed above, cathepsin B is clearly involved 
in the production of IL-1β by activating caspase 1, which in 
turn cleaves pro-IL-1β to produce active IL-1β (116) as has 
been shown in microglia inflamed by fibrillar Aβ or CGA 
or in alveolar macrophages inflamed by silica. Interestingly, 
lysosomal permeabilization and NLRP3 activation are required 
for fibrillar Aβ- (158) and silica- (229) induced inflammations, 
but not in the CGA-induced inflammation (115). Alternatively, 
cathepsin B can also activate IL-1β by cleaving pro-caspase 11 
to activate proinflammatory caspase 11 (230), which in turn can 
cleave pro-caspase 1 (231). As such, cathepsin B can control 
IL-1β activation by multiple mechanisms. Moreover, cathepsin 
B also increases TNFα secretion in response to LPS-induced 
inflammation by functioning in the trafficking of vesicles 
containing TNFα (144). Thus, cathepsin B both contributes to 
TNFα levels and transduction of the TNFα apoptotic cell death 
signal. Cathepsin B also activates IL-18 levels in response to 
CGA-induced inflammation (115).
Peroxisome proliferator-activated receptor (PPAR) recep-
tors are key regulators of neuroinflammation after CNS injury, 
including TBI (232). PPARα agonist fenofibrate is effective in TBI 
TABLe 6 | Small molecule inhibitors of cathepsin B are efficacious for improving behavioral and pathological deficits in TBi and  
TBi-related animal models.
Disease model Compound 
(method)
Compound effects (relative to control) Reference
Behavior Pathology Biomarkers
Trauma TBI E64d (oral, A) ↓ Motor deficits Brain Brain (48)
↓ Lesion vol; neuronal 
death
↓ Cat B; Bax
CA-074Me (icv, B) ↓ Memory deficits Brain Brain (94)
↓ Lesion vol; neuronal 
death
↓ Cat B act; t-Bid; Bax; mito cyt c; caspase 3
z-DEVD-fmk (icv, A) ↓ Motor and cognitive 
deficits
Brain Brain (247)
↓ Lesion vol; Neuronal 
death
↓ Calpain I act; LDH; α-spectrin degradation
LHVS (icv, B) ↓ NNS Brain Brain (248)
↑ Grip strength ↓ Edema; neuronal death ↓ TNFα; IL-1β
Trauma SCC E64d (iv, A) nd Spinal cord
↓ Reactive gliosis
Spinal cord
↓ Calpain act; GFAP; caspase 3; DNA fragments
(249)
Neuroexcitatory 
epilepsy
E64d (ip, B) nd ↓ Brain mossy fiber 
sprouting
Brain mRNA
↓ Cat B; PRG-1; PRG-3; PRG-5; ApoE; 
Clusterin; nSMase
↑ ANX7
(122)
CA-074Me (ip, B) ↑ Neurological scores; 
learning ability
nd Brain
↓ Cat B act; LC3II/LC3I; Beclin-1; Bcl-2; PRG-1
(111)
Neuroexcitatory 
huntington disease
Z-FA-FMK (is, B/A) nd ↓ Brain lesion volume nd (112)
Pain CA-074Me (it, B) ↓ Inflammatory pain nd Microglia: ↓ mIL-1β; mIL-18β (115)
(Continued)
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models (233, 234). PPARδ agonists suppress cathepsin B levels in 
human endothelial cells in a PPARδ-dependent manner (235). 
Thus, PPARδ agonists target cathepsin B and may be beneficial 
in TBI because they reduce cathepsin B.
Axonal Damage
Pathological axonal damage is a predictor of outcome in CNS 
diseases (236) and cathepsin B may be involved in causing that 
damage. As mentioned above, cathepsin B cleaves MARCKS, 
which is the PKC substrate that controls cell morphology and 
motility by regulating actin dynamics near the cell surface. 
N-Methyl-d-aspartate (NMDA) treatment of primary hip-
pocampal neuronal cell cultures mimics excitotoxicity, increases 
cathepsin B, reduces MARCKS at synapses, and causes dendritic 
spine collapse. Treating with CA-074Me, which is a cathepsin 
B inhibitor discussed below, prevents spine collapse in the 
NMDA-treated neurons. (186, 237). Thus, activated cathepsin 
B cleavage of MARCKS may be a mechanism that contributes 
to axonal swelling.
TBi-induced Autophagy
TBI increased autophagy activation within 1 h and up to at least 
3  days after trauma in the brain relative to non-traumatized 
controls as measured by lipidated microtubule-associated 
protein light chain 3 (LC3II) (94, 238–241) with higher LC3II 
levels suggesting autophagy activation (242). Moreover, beclin 
1, which interacts with phosphatidylinositol-3-kinase (Class III 
PI3K) to induce autophagy (243), was also elevated 1 h and up to 
at least 3 days post-TBI in the cortex and hippocampus relative 
to controls (239–241). Furthermore, microscopic examination 
shows more cellular autophagy structures after trauma than 
before (238, 239). Autophagy proteolysis was also increased post-
TBI as measured by P62 with less P62 generally reflecting more 
autophagy proteolysis (244), as P62 was reduced within 1 h and 
up to at least 2 days post-trauma in the cortex and hippocampus 
relative to controls (240, 241).
Inhibiting Autophagy Improves TBI Outcomes
While it has been suggested that autophagy might provide neu-
roprotection after TBI (239), administration of the autophagy 
inhibitor 3-methyladenine (3-MA) to TBI animal models 
reduced the TBI-increased LC3II and Beclin 1 levels and restored 
the reduced P62 levels that resulted from trauma, while improv-
ing memory and neuromotor defects and reducing brain lesion 
volume, neuronal cell death, cathepsin B activity, and caspase 3 
activity (241). 3-MA reduces autophagy by inhibiting Class III 
PI3K and does not inhibit cathepsin B activity (245). Moreover, 
treating animals with the gamma-glutamylcysteinyl ether ester, 
which is a prodrug of glutathione and an antioxidant, also 
reduced autophagy and improved TBI outcomes (238). These 
data suggest that reducing autophagy improves TBI outcomes. 
Cathepsin B inhibitors inhibit lysosomal cysteine proteases, 
which reduces autophagy function (246) and thereby may also 
improve TBI outcomes.
Disease model Compound 
(method)
Compound effects (relative to control) Reference
Behavior Pathology Biomarkers
Infectious brain 
meningitis
CA-074Me (ip, B 
and A)
nd Improved Clinical score; ↓ 
CSF WBC; ICP
↓ Brain IL-1β (42)
Ischemia E64c (ip, B) nd nd ↓ Brain MAP2 degradation (250)
CA-074 (iv, A) nd ↓ Brain neuronal death ↓ Brain cat B (108)
CA-074; E64c (iv, A) nd ↓ Brain neuronal death ↓ Brain cathepsin B activity (109)
CP-1 (iv, A) ↓ Brain infarct volume nd (251)
CA-074, E64c (iv, A) nd ↓ Brain neuronal death nd (252)
E64d (ip, B) nd Brain Brain: ↓ Cat B: Calpain I; Caspase 3; (106)
↓ Infarct vol; neuronal 
death; Edema; vascular 
damage
Vascular: ↓ Cat B; Calpain I; Caspase 3
CP-1 (iv, A) ↓ Neurological defects ↓ Infarct vol. Brain: ↓ Cat B act; Heat shock prot; Serum 
albumin; CRMP2
(110)
Cerebral aneurysm NC-2300 (oral, A) nd Brain
↓ Aneurysms; ECM 
degradation
Aneurysm: ↓ Cat B act; Cat K act; Cat S act
↓ Collagenase; ↑ Elastin
(104)
Cerebral bleeding CP-1 (iv, A) ↓ Motor sensor deficits Brain
↓ Tissue loss; neuronal 
death
↑ Neuronal proliferation
Brain
↑ Synaptophysin; TUJI; Brd; VWF
(253)
Inflammation 
rheumatoid arthritis
E64d (ip B/A) ↓ Clinical symptoms Joint ↓ pathology Joint: ↓ IL-1β; IL-6 (40)
Inflammatory pain 
and edema
K11777 (ip B and A) ↓ Inflammatory pain ↓ Edema; Necrosis; 
pathology
↓ Cat B; Cat L; Cat S; Amylase act
Spinal cord neurons: ↓ c-Fos
(254)
CA-074Me (iv, B) nd ↓ Pathology; edema ↓ Cat B act; Trypsin act; TAP; MPO act; Amylase 
act
(37)
Neuro-degenerative 
AD transgenic 
APPSwe
E64 (ip) ↓ Memory deficits ↑ Long-term potentiation Brain Aβ(1-40/42) no change (255)
Neuro-degenerative 
AD transgenic 
APPLon
E64d (oral) ↓ Memory deficits ↓ Brain Aβ plaque Brain
↓ Aβ(1-40/42); CTFβ
↑ sAPPα
↓ Brain pGlu Aβ(3-40/42)
(256)
E64d (oral) ↓ Brain pGlu Aβ plaque (141)
Neurodegenerative
MS
EAE
LHVS (ip) nd Improved clinical score
↓ Spinal cord leukocyte 
infiltration
↑ Age of onset
↓ Immune cell markers (MHC-II, CD69 CD4+ 
cells)
(146)
B, A, treated before and after inducing pathology, respectively; icv, intracerebroventricular; ip, intraperitoneal; iv, intravenous; is, intrastriatal; it, intrathecal; NNS, neurological 
severity score; ICP, intracranial pressure; CSF WBC, cerebrospinal fluid white blood cells; PRG-2, 3, 5, plasticity related gene 2, 3, 5, respectively; ApoE, apolipoprotein E; sMase 
2, spingomyelinase 2; ANX7, annexin 7; Clusterin, apolipoprotein J; MAP2, microtubule-associated protein; CRMP2, collagen response mediator protein 2; TUJ1, Class III Beta-
tubulin; BrdU, bromodeoxyuridine; VWF, von Willebrand factor; MPO, myeloperoxidase; TAP, trypsinogin activation peptide; GDPH, glycerol-3-phosphate dehydrogenase; ALT, 
alanine aminotransferase; MIP2, macrophage inflammatory protein; KC, chemokine (CXC) ligand; αSMA, α smooth muscle actin; TGFβ, transforming growth factor β; COL1A1, 
collagen α1(I); TIMP, tissue inhibitor of metalloproteinases. Blue and tan colors indicate significant effects on behavior and pathology, respectively, by cathepsin B gene deletion.
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Small Molecule inhibitors of Cathepsin B 
improve Behavioral and Pathological 
Deficits in TBi and TBi-Related Animal 
Models
inhibitors of Cathepsin B improve Deficits of TBi 
Animal Models
Table  6 summarizes the data showing the behavioral, patho-
logical, and biomarker effects of administering small molecule 
inhibitors of cathepsin B to TBI and TBI-related injury animal 
models. These include models of ischemia, subarachnoid and 
cerebral hemorrhage, meningitis, pain, and neurodegenerative 
conditions including epilepsy, AD, MS, and Huntington’s disease. 
Table 7 summarizes the protease inhibition profiles of the small 
molecules cited in Table 6.
The important conclusion from Table  6 is that different 
compounds, which inhibit cathepsin B, used by different groups 
in different TBI animal models resulted in improvements of neu-
romotor and cognitive defects, brain lesion volume, brain edema, 
neuronal cell death, and key brain biomarkers (48, 94, 247, 248). 
A particularly dramatic result is the significant reduction in lesion 
TABLe 7 | Protease inhibition profiles of small molecule inhibitors of cathepsin B, from studies of TBi and TBi-related animals.
Name of inhibitor inhibition profile Notes Reference
e64 (L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane Cathepsins B, L, H, K, S, F, O, V, W, X, 
calpains 1 and 2, and papain
Irreversible inhibitor (70, 257–260)
e64d (EST, Loxistatin, ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-
oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate)
Cathepsins B, L, H, K, S, F, O, V, W, X, 
calpains 1 and 2, and papain
Clinical use
Irreversible inhibitor
(261, 262)
e64c (Loxistatin acid, EP-475, (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)- 
1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylic acid)
Cathepsins B, L, H, K, S, F, O, V, W, X, 
calpains 1 and 2, and papain
Clinical use
Irreversible inhibitor
(261, 263)
CA-074 (N-(L-3-trans-Propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline) Cathepsin B (absolute specificity) Irreversible inhibitor (264–266)
CA-074Me (N-(L-3-trans-Propylcarbonyl-oxirane-2-carbonyl)-L-isoleucyl-L- 
proline methyl ester)
Cathepsins B and L Irreversible inhibitor (267–269) 
LHvS (morpholinurea-leucine-homophenylalanine-vinylsulfone-phenyl) Cathepsins S, B, and L Irreversible inhibitor (146)
Z-FA-FMK (methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2 
(phenylmethoxycarbonylamino)
butanoyl]amino]propanoyl]amino]-4-oxopentanoate)
Cathepsins B, L, and S; caspases 2, 3, 
6, and 7; cruzain; and papain
Irreversible inhibitor (112)
Z-DevD-FMK (methyl (4S)-5-[[(2S)-1-[[(3S)-5-fluoro-1-methoxy-
1,4-dioxopentan-3-yl]amino]-3-methyl-1-oxobutan-2-yl]
amino]-4-[[(2S)-4-methoxy-4-oxo-2-(phenylmethoxycarbonylamino)
butanoyl]amino]-5-oxopentanoate)
Cathepsins B and L, and caspases  
3, 6, 7, 8, and 10
Irreversible inhibitor (247, 270–272)
CP-1 (O-benzyl, OBzl, carbobenoxy, Cbz-Phe-Ser(OBzl)-CHN2, 2[methyl-(4-
phenylbenzoyl)amino]benzoic acid)
Cathepsins B and L Reversible inhibitor (110, 251, 253)
K11777 (N-methyl-Piperazine-Phe-homoPhe-vinylsufone-phenyl) Cathepsins B and L, and cruzain Irreversible inhibitor (43, 273)
NC-2300 (VEL-0230, sodium (2S,3S)-3-(((S)-1-isobutoxy-4-methylpentan-2-yl)
carbamoyl)oxirane-2-carboxylate)
Cathepsins K, B, and S Irreversible inhibitor (104)
Short names of inhibitors are shown in bold. Parentheses indicate other names used for the inhibitor, including chemical names.
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volume as the inhibitors protected against brain tissue loss much 
of which was likely due to necrotic cell death. Another major result 
was the prevention of neuronal cell death in the hippocampus as 
the inhibitors arrested nearly all the cell death that occurs in that 
region as a result of TBI. Behavioral dysfunction was also greatly 
improved by treatment with these compounds suggesting that it 
may be possible to also observe improved clinical outcomes with 
cathepsin B inhibitor treatment of TBI patients.
inhibitors of Cathepsin B improve Deficits in 
TBi-Related Conditions
Compounds, which inhibit cathepsin B, also produced sub-
stantial beneficial effects in TBI-related injuries in animal 
models. For example, neuromotor, neurological learning and 
cognitive defects were improved by cathepsin B inhibition in 
cerebral bleeding (253), ischemia (110), epilepsy (111), and AD 
neurodegeneration (256) animal models. Inflammatory pain 
is a major problem in TBI and was alleviated by cathepsin B 
inhibitors in inflammatory pain models (115, 254). Moreover, 
E64d treatment essentially eliminated the clinical symptoms 
of chronic inflammation due to RA (40) and greatly reduced 
the reactive inflammatory gliosis caused by the trauma of 
SCC (249).
Edema is often a major complication of TBI and compounds, 
which inhibit cathepsin B, reduced edema in ischemic (37, 106) 
and pancreatitis models (254). Excessive ICP and infections also 
often accompany TBI and treatment with a cathepsin B inhibitor 
reduced ICP, improved clinical scores, and lowered CSF white 
blood cell counts in a brain meningitis animal model (42). Brain 
aneurysms and vascular ECM degradation occur as a result of TBI, 
and cathepsin B inhibition stopped aneurysm progression and 
vascular ECM degradation in brain aneurysm (104) and ischemic 
(106) animal models. Brain tissue loss was significantly prevented 
by cathepsin B inhibitor treatment of cerebral bleeding (253), 
ischemia (106, 110, 251), and kainic acid-induced Huntington’s 
chorea animal models (112). Cathepsin B inhibitors have also 
been shown to prevent the vast majority of the neuronal cell death 
that occurs in ischemia (106, 108, 109, 252) and a great deal of 
the death resulting from cerebral bleeding animal models (253).
inhibition of Cathepsin B Modulates TBi 
Biomarkers
The data in Table 6 also show that the inhibitors affected many 
TBI relevant biomarkers. TBI animal models treated with the 
cathepsin B inhibitors had reduced brain pro-apoptotic biomark-
ers including t-Bid, Bcl-2, Bax, cyt c, and caspase 3 (48, 94) and 
inflammatory proteins IL-1β and TNFα (248). The biomarker 
data show that cathepsin B inhibitors improve TBI outcomes in 
part by reducing apoptosis and inflammation.
Glia fibrillary acidic protein (GFAP), which is biomarker of 
CNS inflammation and a potential TBI diagnostic marker (274), 
is reduced by E64d treatment of SCC animals (249). Cathepsin B 
inhibitors also reduced cytokine IL-1β in pain, meningitis, and 
RA animal models (40, 42, 115), IL-18 in a pain animal model 
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(115), and IL-6 in a RA model (40). As in the cathepsin B knock-
out data, cathepsin B inhibitors reduced brain Aβ(1-40/42) and 
pGlu Aβ(3-40/42) in transgenic AD mice expressing human APP 
containing the wt β-secretase site but not in those expressing the 
Swe mutant β-secretase site (141, 256).
These data support the conclusion that compounds, which 
inhibit cathepsin B, are effective in many TBI relevant animal 
models at improving behavior and pathology. As such, these data 
provide strong motivation to explore cathepsin B inhibitors as 
potential TBI therapeutic agents.
e64d is a Promising Drug inhibitor of 
Cathepsin B for Preclinical and TBi 
Therapeutic Drug Development
e64d improves Deficits of TBi and Related 
injuries
TBI and Multiple Injury Conditions are Improved by 
E64d
Most of the preclinical and essentially all the clinical studies on 
small molecule inhibitors of cathepsin B investigated E64 and its 
derivatives E64d, E64c, CA-074Me, and CA-074. Table 6 shows 
that these compounds were efficacious in at least 17 different 
preclinical pathological models including two TBI models as 
well as one SCC, two epilepsy, two pain, one infectious, five 
ischemic, one arthritis, and three neurodegeneration (AD) 
models. Different dosing regimens, including administering 
the drug before or after the pathology onset, have been effec-
tive, as have different routes of administration, including oral, 
intraperitoneal (ip), intravenous (iv), intracerebroventricular 
(icv), and spinal intrathecal (it). Thus, there are robust data 
showing that E64 and its related compounds are efficacious in 
a wide range of TBI-related models using different treatment 
regimens and routes of administration. This is important 
because it is thought that potential TBI therapeutics must 
demonstrate efficacy in diverse animal models in order to have 
hope of success in treating the heterogeneity of TBI injuries in 
a clinical setting (275).
E64d TBI Efficacy is Primarily Due to Cathepsin B 
Inhibition, but Inhibition of Other Proteases Provides 
Added Benefits
Without additional data, it is difficult to conclude that the benefi-
cial TBI effects of E64d are due to cathepsin B inhibition because 
the biologically active acid form of E64d, which is E64c, inhibits 
proteases in addition to cathepsin B, which are the papain-like 
cysteine proteases and calpains 1 and 2 (see section below on 
E64, E64d, and E64c cysteine protease inhibitors). However, the 
relative importance of cathepsin B inhibition can be resolved by 
evaluating E64d in cathepsin B gene-deficient animals. Those 
studies show that E64d treatment produced, with one exception, 
similar improvement in neuromotor deficits after trauma as did 
vehicle controlled treatment of cathepsin B knockout animals 
(48). Also, the E64d-treated cathepsin B knockout animals 
tended to have smaller brain lesion volumes and higher neuronal 
cell densities than vehicle carrier-treated knockout animals but 
the differences were not statistically significant. As such, those 
data argue that E64d acts primarily, but perhaps not exclusively, 
through inhibiting cathepsin B in this TBI model.
The E64d-treated cathepsin B knockout animals per-
formed significantly (20%) better in the neuromotor assay 
than carrier-treated cathepsin B knockout animals on day 1 
post-TBI (48). These results suggest that E64d produced an 
additional benefit in behavior from inhibiting other proteases 
in addition to cathepsin B. While it is impossible to say from 
the data what those other protease(s) are, it is likely that E64c 
inhibition of calpain contributed to the additional benefit. 
That is because calpain activity spikes in the first day after 
TBI (276). Calpain 1 gene-deficient animals have reduced 
brain lesion volume and neuronal cell death following TBI 
(277), and E64d has been shown to inhibit calpain activity 
and provide neuroprotection after trauma (249). Thus, while 
E64c inhibition of cathepsin B is primarily responsible for the 
improvements in the TBI models, its ability to inhibit other 
proteases produces even better outcomes compared to inhibi-
tion of only cathepsin B.
Primary benefits due to inhibiting cathepsin B and the 
additional benefits from inhibiting related proteases have also 
been demonstrated in ischemic non-human primate models. 
CA-074, which has absolute specificity for cathepsin B (see 
below, section on CA-074, selective inhibitor of cathepsin B), 
given iv immediately after ischemia significantly inhibited 
brain cathepsin B by about 75% in the CA1 region of the 
hippocampus and caused substantial neuronal protection by 
saving about 67% of the neurons in that region relative to 
controls (108). Studies comparing the effects of CA-074 with 
that of E64c in the non-human primate model showed that 
even better outcomes resulted from using E64c (109, 252). 
For example, E64c and CA-074 treatments resulted in an 84% 
and 67% CA1 neuronal cell survival, respectively (109), and a 
range of cell protection from 75% (cortical layer 5) to 91.6% 
(cerebellum) vs. 47.4% (CA1) to 89.9% (caudate nucleus), 
respectively, relative to controls (252). The authors attributed 
the increased neuronal cell survival obtained with E64c over 
that of CA-074 to E64c inhibition of cathepsin L and calpains 
in addition to cathepsin B, whereas CA-074 only inhibited 
cathepsin B.
Another advantage of multiple protease inhibition by E64d 
is the indirect reduction in matrix metallopeptidase-9 (MM-9), 
which is a protease that contributes to TBI dysfunction (278). 
Up-regulation of both cathepsin B and calpain causes up-regu-
lation of MMP-9 (279) and since E64c inhibits both cathepsin 
B and calpain, E64d treatment also indirectly down-regulates 
MMP-9 as E64d has been shown to do in an ischemic animal 
model (280).
The cysteine protease inhibitor, morpholinurea-leucine-
homophenylalanine-vinylsulfone-phenyl (LHVS), provides 
significant improvements in behavioral deficits, brain edema, 
and cell survival following TBI (248). LHVS was thought to 
specifically inhibit cathepsin S, which is up-regulated follow-
ing TBI (248), but LHVS has subsequently been shown to 
inhibit cathepsin B, S, and L (146). Thus, the beneficial results 
in the TBI model may be the result of LVHS inhibiting these 
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several proteases. That is the case for the improved outcomes 
seen in an MS model given LHVS in which the compound has 
been shown to act by inhibiting both cathepsins B and S (146). 
E64 has been reported to inhibit cathepsin S (260) and thus 
E64d treatment may also provide beneficial TBI effects through 
inhibiting cathepsin S in addition to that achieved by cathepsin 
B inhibition.
Thus, cathepsin B inhibition is a primary means by which 
E64d provides beneficial outcomes in TBI and ischemic models, 
but additional benefits are obtained by the compound’s inhibi-
tion of other related proteases, especially calpains, cathepsin L, 
and cathepsin S. The ability of E64d to inhibit multiple related 
cysteine proteases is thus an advantage and may be required to 
“move the needle” and affect outcomes in the complex condition 
of TBI.
Biological Effects of Irreversible Cathepsin B 
Inhibition
E64 and its related compounds as well as many other cathepsin B 
inhibitors are irreversible inhibitors meaning that they covalently 
bind to the traget protease and permanently stop that protease’s 
activity. As a result, cathepsin B activity lost due to these inhibitors 
can only be restored through production of new mature cathepsin 
B protein. Normally, cathepsin B turnover (net synthesis and deg-
radation) as measured by the half-life is about 14 h and results in a 
lysosomal content of about 330 mg/g in rat macrophages (87, 92). 
E64 treatment of those cells reduces cathepsin B turnover as the 
cathepsin B half-life is increased 3.6-fold (50 h) and increases lys-
osomal content threefold higher (990 mg/g) relative to untreated 
cells (87, 92). The reduced cathepsin B turnover and increased 
lysosomal content are due to E64 inhibiting the cysteine proteases 
which degrade cathepsin B (87). Thus, irreversible inhibition of 
cathepsin B results in its inactivation as well as increased half-life. 
New synthesis of cathepsin B will be needed to replenish cellular 
levels of active cathepsin B.
Discovery of e64d and Related Compounds
E64, E64d, and E64c Cysteine Protease Inhibitors
The discovery of the epoxysuccinyl-based inhibitor E64 was 
seminal in the development of cathepsin B inhibitors (257). This 
natural product of Aspergillus japonicas selectively inhibits the 
papain-like cathepsin proteases (except cathepsin C) and calpains 
1 and 2. But E64 does not affect cysteine proteases belonging to 
the CD clan, which includes caspases, or proteases belonging to 
the aspartyl, serine or metalloprotease classes or thiol enzymes 
(70, 257–260). For over 30 years, this scaffold has been used to 
develop new compounds having medicinal properties and that 
use continues today (281).
The most important derivative of E64 is E64d (aka EST and 
Loxistatin), which was developed by Taisho Drug Company, 
Japan, and the Japanese Ministry of Health in the 1980s as 
an   experimental therapeutic agent for treating muscular 
 dystrophy (262). The clinical trials in pediatric patients were 
initiated based on studies in which E64d had some, but not 
a great deal, of  effect in a dystrophic hamster model (282). 
The  trials completed through Phase 3, but did not show 
sufficient efficacy for muscular dystrophy and the compound 
did not advance (283).
But importantly, extensive E64d pharmaceutical data were 
published as a result of this effort in many peer-reviewed Japanese 
scientific articles showing that the compounds could be safely 
used in man. Some of those data are summarized below (section 
on pharmaceutical properties of E64d and safety).
E64d is an ethyl ester prodrug, which is hydrolyzed in the 
gut to its active acid form E64c, which systemically circu-
lates and is the biologically active inhibitor form (284). E64c 
has the same inhibition profile as E64, but is more potent 
(285). For example, the potency (IC50) of E64c against rat 
liver cathepsins L, B, H, and porcine kidney calpain 2 is 0.09, 
3.36, 1,640, and 3,000 nM, respectively, with the substrates 
Z-Phe-Arg-MCA, Z-Arg-Arg-MCA, Arg-MCA, and casein, 
respectively (264), indicating varying potencies of E64c for 
inhibition of these cysteine proteases. E64c inhibition of 
calpain 2 is dependent on pH and calcium ion concentration 
and pH (286). Thus, oral administration of E64d results in 
systemic circulation of E64c, which can inhibit cathepsins B, 
L, K, H, O, S, V, W, and X, and calpains 1 and 2, but not other 
proteases or thiol-containing enzymes.
CA-074, Selective Inhibitor of Cathepsin B, and 
CA-074Me
A specific inhibitor of cathepsin B was developed from the E64 
template, known as CA-074, which irreversibly inhibits with 
high potency (264, 265). CA-074Me was developed from CA-074 
to have better membrane permeability (269) but inhibits both 
cathepsin B and L (267, 268).
E64 Activity-Based Probes (ABPs)
E64 has given rise to activity-based probes (ABPs), which bind 
to the active site of proteases and report on activities via a biotin 
or quencher-fluorophore tag (287–289). ABPs have been used 
to affinity purify cathepsin B activity from regulated secretory 
vesicles of chromaffin cells to discover its β-secretase activity 
in those vesicles (148). ABPs can image proteases in vivo (254, 
290, 291) and would provide powerful visual data on cathepsin B 
distribution in TBI. ABPs can evaluate a drug’s engagement with 
cathepsin B (290). ABPs could be adapted to evaluate inhibitor 
target engagement with brain cathepsin B in animal models and 
in the clinic.
Pharmaceutical Properties of e64d
Oral and Peripheral E64d Administration is 
Efficacious in Animal Models
An important result from a TBI translational point of view is that 
oral administration of E64d (one 10 mg/kg dose) has been shown 
to be efficacious in a TBI animal model when given up to 8 h 
after trauma (48). That is a key milestone because 8 h represents 
a time frame in the TBI animal model for drug administration 
that could be applied post injury in the clinic. In most clinical 
TBI therapeutic applications, the earliest time when therapy can 
begin is about 6 h after injury and, thus, it is critical that a com-
pound is effective at times after the TBI injury event in the animal 
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model. Moreover, the data discussed above show that cathepsin 
B remains elevated for days after injury suggesting that an even 
longer effective treatment window is likely.
Furthermore, administration of E64d by oral gavage to guinea 
pigs (1–10 mg/kg/day, 7 days) resulted in dose–response reduc-
tions in brain cathepsin B activity and Aβ (256). And feeding 
E64d (10 mg/kg/day, 1 to 2 months) in chow to transgenic mice 
also reduced brain Aβ and pGluAβ (141, 256). Moreover, icv E64c 
(4 mg/kg) administration reduced brain cathepsin B activity in 
ischemic monkey models (109, 252) and ip E64d administration 
inhibited brain cathepsin B activity in ischemic rat (5  mg/kg) 
(106) and epileptic rat (4 μg dose) models (122). Thus, oral and 
other peripheral routes of E64d administration at doses compara-
ble to that used in man (5 mg/kg/day) have been shown to inhibit 
cathepsin B and affect brain biomarkers in animal models.
E64d/E64c Biodistribution
Radioactive E64d biodistribution studies show that about 60% of 
an oral E64d dose is taken up in rats and hamsters and most of 
that occurs in the small intestine. Blood levels quickly rise and the 
maximum blood concentration varies among animal species with 
rabbits having the highest, and hamsters, dogs, and rats having 
75%, 33%, and 25% that of rabbits, respectively. The excretion also 
varies among species, with most occuring via the urine in rabbits 
and hamsters whereas the feces was the primary route in dogs and 
rats. Biliary excretion was greater than 50% and 13% of the dose 
in rats and hamsters, respectively. Respiration only accounted for 
about 7% of the dose (292).
The tissue distribution was similar for rats, rabbits, and ham-
sters, but the highest drug concentration was in the gastrointestinal 
track followed by the kidney and liver which had about 25- and 
12-fold higher concentrations than the plasma concentration, 
respectively. But the brain concentration was one-tenth that of 
the plasma concentration. However, the liver drug concentration 
in rats was about twice that of hamsters (293).
At a cellular level, subcutaneous radioactive E64c injection of 
rats resulted in a muscle cytoplasm to lysosome-specific activity 
ratio of about 5:1 (294). That distribution is advantageous for 
TBI treatment because the drug is concentrated in the cytoplasm 
where it is needed in the injury condition and not in the lysosomes 
where it could interfere with normal proteolysis.
E64d Pharmacokinetics and Metabolites
Pharmacokinetic properties of E64d have been determined in 
animals and man (284, 295, 296, 297). In man, an oral E64d dose 
is completely hydrolyzed in the gut to the acid form of E64c which 
systemically circulates and about half of that is metabolized to 
two hydroxylated E64c metabolites (M4a and M4b). E64c and M4 
have about the same area under the curve (AUC) values (5.08 μg-
hr/mL), serum half-lives of about 1.34 and 2.5 h, respectively, and 
urinary excretion rates of 28.9% and 18.5%, respectively. Single 
and multi-dose pharmacokinetics are the same, the drug does 
not accumulate and is completely eliminated within 24 h of the 
last dose in the urine at a recovery rate is about 30%. The M4 
metabolites have the same inhibitory profile as E64c. Once a day 
dosing is effective despite the relatively short half-lives because 
the compounds are potent irreversible inhibitors.
E64d Mutagenesis
In vitro E64d mutagenic studies using the reverse mutation (Ames 
bacterial cell test) and chromosome aberration test (Chinese 
hamster lung fibroblast cells) showed no mutations or chromo-
some aberrations. In  vivo mutagenic studies using the mouse 
bone marrow chromosome aberration test showed that E64d did 
not have any effects in that assay. The conclusion was that E64d is 
unlikely to have mutagenic effects (298).
E64d Toxicology
Toxicity studies show that E64d has a wide therapeutic window. 
Extensive E64d toxicology studies have been published. For 
example, acute oral E64d toxicity studies showed that high lethal 
doses to be over 10,000 and 5,000 mg/kg for rats and dogs, respec-
tively, which killed 50% of the animals (LD50), with the main 
clinical effects being depression of voluntary movements, closed 
eye, and loss of righting reflex, from which it was concluded that 
acute toxicity is not an issue (299). Longer-term toxicity studies 
showed the kidneys and liver to be the primary target organs 
for toxicity and the toxic effects increased with increasing dose 
and generally abated upon discontinuing the drug. Sub-acute, 
1 month oral E64d toxicity studies in dogs and rats found no-
effect doses of 40 and 80 mg/kg/day, respectively, with slight renal 
tubular epithelia degeneration but without an increase in renal 
weight or impairment of function (300, 301). Six-month chronic 
oral E64d studies in dogs found a no-dose effect level at 5 mg/kg/
day, with similar renal results as in the sub-acute studies (302). 
Six-month chronic oral E64d studies in rats, on the other hand, 
found a no-effect dose of 2 mg/kg/day for liver toxicity and10 mg/
kg/day for renal toxicity and that the rat was unusually sensitive to 
liver toxicity (303). Subsequent studies confirmed the rat species-
specific hepatotoxicity as a single oral E64d dose produced rat 
liver toxicity at 60 mg/kg, but in a hamster liver toxicity required a 
500 mg/kg dose (297, 304). The rat liver toxicity was attributed to 
the rat metabolizing the drug differently than rabbits, hamsters, 
and man because the rat mostly excreted the drug as glutathione 
conjugates via bile whereas in man and other animals the free 
drug was mostly excreted via urine (284). Rats have much higher 
liver glutathione levels, which E64c and M4 metabolites bind to, 
and thus the rat liver dose is proportionally greater than that in 
other species (304).
E64d Teratogenic Effects
Teratogenic effects have also been studied and also show dif-
ferences among species. In rabbits, the no teratogenic effect for 
oral E64d doses was found to be 100 and 500  mg/kg/day for 
fetuses and mothers, respectively, when administered from the 
6th through the 18th day of gestation (305). By contrast, the no 
teratogenic effect oral E64d dose in rats was 20 mg/kg/day for 
fetuses and mothers when given at about the same time frame 
(7th through the 17th day of gestation) (306). Thus, the rat is 
much more susceptible to E64d teratogenic effects than rabbits. 
Rat studies using oral dosing before pregnancy and during mat-
ing and late-term and post-natal showed the lowest no-effect 
dose for the fetuses and parents to be about 50 and 80 mg/kg/day 
(307, 308). No effect was seen in the subsequent generation (F2) 
in these studies.
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e64d Safely Used in Man
As mentioned above, E64d was developed for treating muscular 
dystrophy. Phase 1 single (oral 3.5 mg/kg maximum dose) and 
multi-dose (oral, 5  mg/kg/day for 7  days) studies in normal 
volunteers and showed no effect on observed clinical symp-
toms, including electrocardiograms, body temperature, blood 
pressure, grip strength, and physician interviews, or clinical 
tests, including hematological tests, blood chemistry tests, and 
urinalysis (295, 296). These E64d doses used in patients are 
below the range of doses evaluated in animals for toxicology and 
teratogenic studies.
Open trials on 73 Duchene’s muscular dystrophy patients were 
conducted for 3 years at four Japanese national sanatoriums and 
resulted in some muscle strength improvement but the results 
were inconclusive and final double-blind studies did not confirm 
the results (283). The fact that these trials were completed shows 
that no serious adverse event occurred in the pediatric patient 
population with long-term chronic administration of E64d.
issues with e64d TBi Therapy
The gross abnormalities seen in offspring of double cathepsin B 
and L knockout mice clearly show that some cysteine cathepsin 
activity is required for normal embryogenesis. Possibly, the loss of 
cysteine cathepsin protease protein degradation in lysosomes and 
autophagosomes results in nutritional deficiencies, which cause 
the abnormalities. As discussed above, sufficiently high E64d 
doses can also cause teratogenic abnormalities when adminis-
tered to pregnant animals.
This has consequences for the therapeutic use of E64d or its 
derivative, the most obvious being that very careful considera-
tion will have to be given to its use in pregnant women, women 
of child-bearing age, and infants. But as most young civilian 
and military TBI patients are adolescent or young adult males, 
the teratogenic danger may not be as much of a risk for the 
majority of that TBI patient population. Moreover, the terato-
genic risk is not likely an issue for a large and growing segment 
of the TBI population, which are elderly who are beyond the 
reproductive age.
These data also suggest that minimizing inhibition of 
lysosomal cathepsin B and cathepsin L activities is desirable in 
adults. To that end, E64c is unique among cysteine protease 
inhibitors in that it concentrates in the cytosol and not in the 
lysosome (see above section on E64d/E64c biodistribution), 
thus preferentially spares inhibition of lysosomal cathepsin B 
and L activities. The fact that E64d has been safely administered 
to pediatric patients for many years shows that, if lysosomal 
protease inhibition is a toxicity issue, it is not significant with 
an appropriate dose.
The low brain dose is the primary issue with E64d as a 
TBI therapeutic because a small portion of an oral dose gets 
into the brain as discussed above (section on biodistribution). 
Even though a low brain dose can effectively inhibit brain 
cathepsin B activity, it would be desirable to have a deriva-
tive compound, which delivers a higher brain dose than does 
E64d so that efficacy could be achieved with reduced systemic 
exposure.
e64d is a Promising Tool Compound for 
Preclinical TBi Testing and TBi Clinical 
Compound Development
E64d is unique among the small molecule cathepsin B inhibitors 
because of the extraordinary amount of data on the compound. No 
other compound has the extensive information known for E64d 
on its efficacy, toxicology, and safety. These data greatly reduce 
the risk of using E64d vs. other small molecule compounds for 
testing in TBI and related models. Therefore, E64d is a promising 
tool compound for preclinical TBI testing.
The extraordinary amount of data makes the E64d scaffold 
extremely useful for developing clinical derivatives. Only the E64d 
compound has data on pharmaceutical properties that provides 
an expectation roadmap for the behavior of a clinical compound 
that is derived from it. Other small molecule scaffolds lack that 
information and thus all the data on clinical candidates derived 
from them will be without information as to the likelihood of 
pharmaceutical success. Thus, the E64d data greatly reduce the 
inherently high risk of drug development.
One might ask why not use a cathepsin B-specific inhibitor 
rather than the multi-protease inhibitor E64d since cathepsin B 
knockouts have no pathology? A druggable cathepsin B-specific 
inhibitor may be useful as a follow-on therapeutic. However, no 
orally bioavailable, brain effecting, cathepsin B-specific inhibitor 
is currently available and developing such will be difficult and 
will take considerable resources and time. For example, a high 
throughput screen of the National Institutes of Health (NIH) 
small molecule library for a cathepsin B-specific inhibitor did 
not find a druggable hit (309). The known cathepsin B-specific 
inhibitor, CA-074, is not orally druggable and when made more 
so with the addition of a methyl group, it looses specificity. Thus, 
an E64d derivative will likely reach clinical testing much sooner 
than a cathepsin B-specific compound.
TBI is an urgent unmet need that cannot wait. Furthermore, as 
discussed above, the multi-cysteine protease inhibition by E64c 
is more efficacious than selective cathepsin B inhibition and 
thus E64d derivatives offer a better chance of obtaining positive 
outcomes in clinical trials.
Conclusion
Cathepsin B gene deletion studies show that cathepsin B is a 
key player in the pathology of TBI. Cathepsin B is elevated fol-
lowing TBI and its removal or inhibition dramatically improves 
outcomes following trauma in animal models. Moreover, deleting 
or inhibiting cathepsin B improves outcomes in injury models 
related to TBI including epilepsy, aneurysm, ischemia, pain, 
surgical trauma, spinal cord trauma, infectious disease, and neu-
rodegeneration. E64d is a promising compound for further pre-
clinical testing as a candidate therapeutic agent for TBI because 
it has been shown to be orally effective when administered after 
trauma. E64d is the best scaffold upon which a TBI therapeutic 
can be developed because only E64d has extensive clinical and 
preclinical data available. It will also be beneficial to consider that 
inhibition of cathepsin B targets several mechanisms involved 
in TBI, including calpain and matrix metalloproteinases that 
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contribute to TBI, as explained in this review. In conclusion, 
basic and translational research on cathepsin B for improving 
TBI-caused deficits should be accelerated as it is highly likely to 
generate an effective new TBI therapeutic.
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